Get the Stockscreener App
19.80
3.61%
0.69
After Hours:
18.88
-0.92
-4.65%
Cartesian Therapeutics Inc stock is traded at $19.80, with a volume of 75,062.
It is up +3.61% in the last 24 hours and down -19.25% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
See More
Previous Close:
$19.11
Open:
$19.13
24h Volume:
75,062
Relative Volume:
0.80
Market Cap:
$473.15M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-51.37M
1W Performance:
-11.41%
1M Performance:
-19.25%
6M Performance:
-22.66%
1Y Performance:
+0.00%
1-Day Range:
$19.05
$20.34
1-Week Range:
$18.85
$22.90
52-Week Range:
$11.66
$42.60
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
617-923-1400
Address
704 QUINCE ORCHARD RD, GAITHERSBURG
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - The Manila Times
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance
Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat
30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN
Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa
Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World
Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat
Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpHere's Why - MarketBeat
Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily
Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle
Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Logos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Point72 Asia Singapore Pte. Ltd. Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Logos Global Management LP Purchases Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
1,725 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Acquired by Point72 DIFC Ltd - Defense World
Rhumbline Advisers Sells 121,396 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Rhumbline Advisers Has $229,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Mizuho affirms Outperform on Cartesian Therapeutics stock, highlights Descartes-08’s competitive edge - Investing.com Canada
Logos Global Management LP Invests $2.43 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance By Investing.com - Investing.com Australia
Logos Global Management LP Buys Shares of 90,000 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Bank of New York Mellon Corp Has $538,000 Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics gets shareholder nod for stock issuance - Investing.com
Cartesian Therapeutics Puts Talent and Innovation at the Heart of the Organization - BioBuzz
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics Receives FDA Rare Pediatric Disease - GlobeNewswire
FDA grants rare pediatric status for Cartesian’s Descartes-08 - The Pharma Letter
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment - MarketWatch
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis - Yahoo Finance
Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma - CGTLive™
Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewswire
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics shares maintain Buy rating as new trial kicks off - Investing.com Canada
Cartesian advances new mRNA therapy into Phase 1 trial - Investing.com India
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cartesian Therapeutics Inc Stock (RNAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | Director |
Oct 04 '24 |
Buy |
22.58 |
80,301 |
1,813,010 |
8,023,766 |
| SPRINGER TIMOTHY A | Director |
Oct 02 '24 |
Buy |
17.38 |
5,514 |
95,822 |
7,823,559 |
| SPRINGER TIMOTHY A | Director |
Aug 12 '24 |
Buy |
12.72 |
8,016 |
101,968 |
11,509 |
| BARABE TIMOTHY C | Director |
Aug 12 '24 |
Buy |
12.70 |
7,500 |
95,250 |
21,766 |
| SPRINGER TIMOTHY A | Director |
Mar 08 '24 |
Buy |
0.66 |
4,800 |
3,187 |
95,218 |
| SPRINGER TIMOTHY A | Director |
Mar 13 '24 |
Buy |
0.58 |
3,200 |
1,868 |
100,818 |
| SPRINGER TIMOTHY A | Director |
Feb 07 '24 |
Buy |
0.66 |
2,400 |
1,575 |
90,418 |
| SPRINGER TIMOTHY A | Director |
Mar 14 '24 |
Buy |
0.53 |
2,000 |
1,061 |
102,818 |
| SPRINGER TIMOTHY A | Director |
Mar 11 '24 |
Buy |
0.65 |
1,200 |
785 |
96,418 |
| SPRINGER TIMOTHY A | Director |
Mar 12 '24 |
Buy |
0.61 |
1,200 |
735 |
97,618 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):